30 Participants Needed

Platelet Rich Plasma for Foot Ulcer

Recruiting at 1 trial location
ML
TI
Overseen ByTarek Ibrahim, MBA
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Estar Medical dba Medical Technologies, LTD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2, mild to moderate, neuroischemic diabetic chronic foot ulcers in subjects with Type 1 and Type 2 Diabetes Mellitus. The main question\[s\] it aims to answer \[is/are\]:Measure 1: Wound Closure with Tropocells Autologous PRF System for DFU Measure 2: Safety of Tropocells Autologous PRF System for DFU Researchers will enroll to acquire approximately 30 evaluable subjects with no comparison group.Run-In Phase (2 weeks): participants with chronic diabetic foot wounds will undergo a 2-week run in phase presenting to the clinic for weekly visits, for standard of care.Active Treatment Phase (12 weeks): participants that do not show a reduction of at least 20% may be qualified to advance to the active treatment phase where wounds will be evaluated and treated weekly in the research clinic to receive standard of care with Tropocells Autologous PRF System.Follow-up Phase (1 month and 3 months): participants with wounds that losed during the Active Treatment Phase ( 100% wound closure with two weekly assessments demonstrating persistent closure) will be advanced to the follow-up phase to show if the wound remains closed at 1 month and 3 months.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on systemic corticosteroids or certain treatments that affect wound healing, you may need to stop them 30 days before the study. It's best to discuss your specific medications with the trial team.

Is platelet-rich plasma safe for treating foot ulcers?

Research shows that platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) have been used safely in treating diabetic foot ulcers and other chronic wounds. These treatments are generally considered safe, but results can vary due to differences in how they are prepared.12345

How is the treatment Tropocells Autologous Platelet-rich Fibrin (PRF) unique for foot ulcers?

Tropocells Autologous Platelet-rich Fibrin (PRF) is unique because it uses the patient's own blood components to create a fibrin matrix that promotes healing, unlike standard treatments that may not use autologous (self-derived) materials. This approach can enhance wound healing by providing a scaffold for cell growth and delivering growth factors directly to the ulcer site.13567

What data supports the effectiveness of the treatment Tropocells Autologous Platelet-rich Fibrin (PRF) for foot ulcers?

Research shows that using platelet-rich plasma (PRP), which is similar to PRF, can help heal diabetic foot ulcers. Studies have found positive outcomes in wound healing when PRP is used, although results can vary due to differences in how PRP is prepared.13458

Who Is on the Research Team?

AP

Adrianne P Smith, MD

Principal Investigator

Sanogenix Medical, LLC

ML

Marcus L. Gitterle, MD

Principal Investigator

WoundCentrics

Are You a Good Fit for This Trial?

This trial is for males and females aged 18-80 with Type 1 or Type 2 Diabetes Mellitus who have chronic neuroischemic diabetic foot ulcers graded as mild to moderate (Wagner Grade II). Participants should not show at least a 20% wound reduction during a run-in phase to qualify for the active treatment.

Inclusion Criteria

I don't have signs of infection in my wound or limb.
I use a special boot or device to relieve pressure on my foot.
I am able to bear children, not pregnant, and will use birth control or abstain during the trial.
See 19 more

Exclusion Criteria

I have not had sepsis in the last 2 weeks.
I have a history of blood clotting issues or am on IV heparin.
I have had radiation or chemotherapy in the last 3 months.
See 20 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2 weeks
2 visits (in-person)

Run-In

Participants with chronic diabetic foot wounds undergo a 2-week run-in phase with standard of care including nutritional supplementation, wound assessment, and care.

2 weeks
2 visits (in-person)

Active Treatment

Participants receive weekly treatment with Tropocells Autologous PRF System and standard of care for wound care.

12 weeks
12 visits (in-person)

Follow-up

Participants are monitored to ensure wounds remain closed at 1 month and 3 months post-treatment.

3 months
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Tropocells Autologous Platelet-rich Fibrin (PRF)
Trial Overview The study tests Tropocells Autologous Platelet-rich Fibrin (PRF) in wound care. It involves an initial run-in phase, followed by up to 12 weeks of treatment with PRF for those whose wounds don't shrink by at least 20%, and then follow-up after wound closure at one and three months.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: T1DM,T2DM participants with non-infected, neuroischemic, chronic foot ulcersExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Estar Medical dba Medical Technologies, LTD

Lead Sponsor

Trials
1
Recruited
30+

WCG IRB

Collaborator

Trials
2
Recruited
1,000+

Citations

A case series of autologous platelet-rich plasma injection in treating chronic ulcers conducted in Saudi Arabia. [2023]
Efficacy and safety of autologous platelet-rich plasma for diabetic foot ulcers: a systematic review and meta-analysis. [2023]
Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer. [2021]
Management of chronic diabetic foot ulcers using platelet-rich plasma. [2022]
Wound Healing in Diabetic Foot Ulcer Patients Using Combined Use of Platelet Rich Fibrin and Hyaluronic Acid, Platelet Rich Fibrin and Placebo: An Open Label, Randomized Controlled Trial. [2022]
Utility of platelet rich fibrin gel therapy in nonhealing ulcer secondary to ecthyma gangrenosum. [2020]
Use of platelet rich plasma and hyaluronic acid on exposed tendons of the foot and ankle. [2010]
Use of autologous platelet rich fibrin-based bioactive membrane in pressure ulcer healing in rats. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security